PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerview.com

subscribe
share





Concetta (Connie) DiDomenico, RN, MSN, PNP-BC, CPHON / Michael J. Fisher, MD - Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1, Plexiform Neurofibromas, and Optic Pathway Gliomas: Improving Patient Outcomes With an Innovative Therapeutic Approa


Go online to PeerView.com/BQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. In this educational on-demand activity, an expert panel provides insights into the expanding landscape of targeted therapies and discusses optimal clinical decision-making for patients with NF-1 and NF-1─related plexiform neurofibromas based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF-1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas and other NF-1–associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF-1–related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF-1–related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF-1–related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.


share







 2020-11-03  1h4m